For the year 2019, the Ministry of Health will allocate R$ 1.3 billion to ensure the purchase of medications planned for the treatment of hereditary bleeding disorders, including hemophilia A and B, within the Unified Health System (SUS). The announcement from the ministry coincides with International Hemophilia Day. In Brazil, in 2018, 26,700 patients were registered in the Hemovida Web Coagulopathies system, which gathers information from all 
treatment centers in the country. Of this total, 39.52% have a diagnosis of hemophilia A and 7.84% of hemophilia B.
“Currently, the Ministry of Health provides hemophilia patients with Recombinant Factor VIII, aimed at treating hemophilia A, the most prevalent type in the country. We also offer comprehensive care to these patients and their families. But we will further expand this support through our network, which is a reference for several countries,” said the Minister of Health, Luiz Henrique Mandetta. For 2019, the ministry has already acquired 720 million international units 
of the input.
International Hemophilia Day is a date that marks the global pursuit of improving the quality of life for those affected by this hereditary and genetic disease. Since 2004, in Brazil, the Ministry of Health has consolidated a National Program, within the National Blood, Components, and Derivatives Policy, which has been considered a model for other countries. However, the ministry continues its efforts to maintain what has already been implemented and to further enhance care and attention for patients with hemophilia and other hereditary bleeding disorders.
Hemophilia is a genetic-hereditary disease that predominantly affects males. It is characterized by a deficiency of coagulation factors VIII (hemophilia A) and IX (hemophilia B) in the blood of individuals. 
The clinical effects of the disease include bleeding episodes, which can lead to various complications, such as joint and limb impairment.
The treatment of hemophilia is done through the replacement of the deficient coagulation factor (factor VIII or factor IX) and has evolved significantly over the last 40 years, from blood transfusion procedures in the 1940s to the use of purified human plasma coagulation factor concentrates and, more recently, recombinant pro-coagulant medications. The factor concentrates are distributed by the Ministry of Health to state hemophilia treatment centers.
Source: Ministry of Health